Sertraline
Sertraline, Zoloft (sertraline) is a small molecule pharmaceutical. Sertraline was first approved as Zoloft on 1991-12-30. It is used to treat depressive disorder, feeding and eating disorders, obsessive-compulsive disorder, panic disorder, and post-traumatic stress disorders in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Sertraline, Zoloft (discontinued: Sertraline, Zoloft)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| sertraline | ANDA | 2024-11-04 |
| sertraline hcl | ANDA | 2024-05-16 |
| sertraline hydrochloride | ANDA | 2024-10-25 |
| sertraline hydrochloride tablets | ANDA | 2009-08-20 |
| zoloft | New Drug Application | 2023-08-15 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
408 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 8 | 39 | 46 | 61 | 74 | 219 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 11 | 38 | 48 | 55 | 58 | 200 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 7 | 21 | 22 | 30 | 33 | 110 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 4 | 5 | 8 | 13 | 7 | 35 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 1 | 7 | 5 | 9 | 11 | 31 |
| Traumatic stress disorders | D040921 | — | — | 3 | 4 | 7 | 10 | 4 | 26 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 2 | 3 | 8 | 8 | 20 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 2 | 3 | 8 | 6 | 18 |
| Healthy volunteers/patients | — | — | — | 14 | — | — | 2 | 2 | 18 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 2 | 5 | 3 | 3 | 13 |
Show 53 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | — | 3 | 5 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | 1 | — | 3 | 5 |
| Heart failure | D006333 | HP_0001635 | I50 | — | 1 | 1 | — | 3 | 4 |
| Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 3 | 1 | — | — | 4 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | 1 | — | 3 | 4 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 1 | 1 | 2 | — | — | 4 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | — | 1 | 2 | — | 1 | 3 |
| Separation anxiety | D001010 | EFO_1001916 | — | — | — | 1 | — | 2 | 3 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 1 | — | 1 | 3 |
| Brain injuries | D001930 | — | S06.9 | — | 1 | 1 | — | 2 | 3 |
Show 30 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | — | 3 | — | — | 1 | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | — | 2 | 4 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 2 | 1 | — | — | 1 | 3 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | — | 2 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | — | — | 1 | 2 |
| Hepatitis c | D006526 | — | B19.2 | 1 | 1 | — | — | — | 2 |
| Fragile x syndrome | D005600 | — | Q99.2 | — | 2 | — | — | — | 2 |
| Cocaine-related disorders | D019970 | — | F14 | — | 2 | — | — | — | 2 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 2 | — | — | — | 2 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 1 |
Show 22 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 1 | 2 |
| Huntington disease | D006816 | Orphanet_399 | G10 | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
| Vertigo | D014717 | — | H81.39 | 1 | — | — | — | — | 1 |
| Dizziness | D004244 | HP_0002321 | R42 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Taste disorders | D013651 | — | — | — | — | — | — | 3 | 3 |
| Psychological distress | D000079225 | — | — | — | — | — | — | 3 | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 2 | 2 |
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | — | — | — | 2 | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | — | — | — | 2 | 2 |
| Affective symptoms | D000342 | — | — | — | — | — | — | 2 | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
| Hot flashes | D019584 | — | — | — | — | — | — | 2 | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 1 | 1 |
| Covid-19 | D000086382 | — | — | — | — | — | — | 1 | 1 |
Show 62 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Sertraline |
| INN | sertraline |
| Description | Sertraline is a member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. It has a role as an antidepressant and a serotonin uptake inhibitor. It is a member of tetralins, a secondary amino compound and a dichlorobenzene. It is a conjugate base of a sertraline(1+). It derives from a hydride of a tetralin. |
| Classification | Small molecule |
| Drug class | selective serotonin reuptake inhibitors (SSRI) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 79617-96-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL809 |
| ChEBI ID | 9123 |
| PubChem CID | 68617 |
| DrugBank | DB01104 |
| UNII ID | QUC7NX6WMB (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
Sertraline
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,030 documents
View more details
Safety
Black-box Warning
Black-box warning for: Sertraline, Sertraline hcl, Sertraline hydrochloride, Sertraline hydrochloride tablets, Zoloft
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
80,896 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use